Gian-Carlo Giove, MD
Cardiovascular Disease · Tallahassee, FLNPI 1700194966
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $151,534 of the $231,247 with a category attached, or 65.5%. 39 manufacturers reported payments, led by Merck at 32.0% of the total. Reporting peaked in 2022 at $65,433 and has fallen 52.4% since, to $31,149 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,531 payments — averaging $151.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$74K
- Boehringer Ingelheim$42K
- Bayer$33K
- Lilly USA, LLC$26K
- AstraZeneca$17K
- Bridgebio Pharma, Inc.$11K
- plus $28K from 33 others
Across 18 payments — averaging $3267.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$59K
- Abbott$45
What the payments were for
- Consulting fees$13,9686%
- Speaking & faculty fees$151,53466%
- Travel & lodging$30,45013%
- Food & beverage$34,81015%
- Education$4840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$101,409
- JARDIANCE$65,242
- Kerendia$30,061
- FARXIGA$14,391
- Attruby$10,944
- VYNDAQEL$3,359
- Barostim Neo System$1,541
- Adempas$1,458
- Impella$1,353
- Rapiblyk$1,266
- Repatha$1,104
- TYVASO$466
- ORENITRAM$456
- LifeVest$355
- SYMPLICITY G3$292
- CARDIOMEMS$283
- Assure WCD$173
- MitraClip System$158
- Reveal LINQ$152
- ELIQUIS$128
How this compares
$231,247 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 279 | $3,568,350 |
| AdempasRiociguat | 168 | $2,339,307 |
| VyndamaxTafamidis | 94 | $2,116,427 |
| EntrestoSacubitril/Valsartan | 1,034 | $907,690 |
| JardianceEmpagliflozin | 1,009 | $780,352 |
| UptraviSelexipag | 20 | $663,222 |
| FarxigaDapagliflozin Propanediol | 797 | $656,888 |
| WinrevairSotatercept-Csrk | 36 | $627,764 |
| Tyvaso DpiTreprostinil | 17 | $398,632 |
| EliquisApixaban | 449 | $347,669 |
| CamzyosMavacamten | 31 | $239,049 |
| Repatha SureclickEvolocumab | 201 | $180,508 |
| Orenitram ErTreprostinil Diolamine | 26 | $177,987 |
| OpsynviMacitentan/Tadalafil | 13 | $170,871 |
| KerendiaFinerenone | 123 | $116,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $1,572 | $4,402,444312 claims |
| PfizerVyndamax, Eliquis | $5,028 | $2,464,097543 claims |
| BayerAdempas, Kerendia | $33,225 | $2,455,331291 claims |
| NovartisEntresto | $1,866 | $907,6901,034 claims |
| Boehringer IngelheimJardiance | $42,082 | $780,3521,009 claims |
| AstraZenecaFarxiga, Brilinta | $17,046 | $680,213841 claims |
| MerckWinrevair, Verquvo | $73,967 | $659,68975 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $1,317 | $239,04931 claims |
| Johnson & JohnsonXarelto | $453 | $100,512140 claims |
| Novo NordiskWegovy, Ozempic | $735 | $73,20665 claims |
| AmgenCorlanor | $2,421 | $55,13575 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $118 | $6,80713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Tallahassee
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.